Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.

对晚期卵巢癌患者在长期临床前有效治疗后，获得对节拍式口服拓扑替康化疗联合帕唑帕尼耐药性的分析